The global wollastonite market is projected to grow at a 3.5% CAGR, reaching $398 million by 2035. Growth is fueled by rising demand in adhesives, construction, automotive, and plastics sectors, especially in the Asia-Pacific region due to rapid industrialization and infrastructure development. Natural wollastonite leads growth due to lower costs and availability. Innovations in processing and sustainability trends are expanding applications in green building, automotive components, and electronics. Challenges include supply concentration and competition from alternative fillers. Market players focus on capacity expansion, R&D, and strategic partnerships to capitalize on emerging opportunities.
The global wollastonite market outlook is provided here with Pluang's Basic Materials sector data as of Nov 06, 2026 19:12 WIB. For readers following Basic Materials, of 83 US stocks priced on Pluang, 36 rose and 46 fell today. Notable movers include ESI at USD 31.56 (+2.60%, typical hold time 28 days), SSL at USD 14.81 (-2.50%, typical hold time 6 days), and ALM at USD 8.13 (+2.26%, typical hold time 6 days).
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
